// App-Quantinova.ai

: Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: Results from the LINC 3 study

Researchers

Presenter

  • Rosario Pivonello

Principal Investigators

  • Maria Fleseriu

  • John Newell-Price

  • Xavier Bertagna

  • James Findling

  • Akira Shimatsu

  • Feng Gu

  • Richard Auchus

  • Rattana Leelawattana

  • Eun Jig Lee

  • Jung Hee Kim

  • Andre Lacroix

  • Audrey Laplanche

  • Paul O’Connell

  • Alberto M Pedroncelli

  • Libuse Tauchmanova

  • Beverly MK Biller

Medical Centers

  • Universita Federico II di Napoli, Napoli, Italy

  • Northwest Pituitary Center, Oregon Health & Science University, Portland, OR

  • Medical School, University of Sheffi eld, Sheffi eld, UK

  • Department of Endocrinology, Centre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris V, Paris, France

  • Division of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, WI

  • Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

  • Department of Neurosurgery, Peking Union Medical College Hospital., Beijing, China

  • Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI

  • Pituitary Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea

  • Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Novartis AG, Basel, Switzerland

  • Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA

Locations

  • Italy

  • United States

  • United Kingdom

  • France

  • Japan

  • China

  • Thailand

  • Canada

  • Switzerland

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Pituitary adenoma 4, ACTH-secreting

  • Depression

Biomarkers

  • N/A

Drug/Treatment

  • LCI699

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved